UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000051265
Receipt number R000058455
Scientific Title A study to confirm the reduction effect of the test food on abdominal visceral fat. -Randomized, double-blind, placebo-controlled parallel group study-
Date of disclosure of the study information 2023/06/05
Last modified on 2023/12/04 11:05:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study to confirm the reduction effect of the test food on abdominal visceral fat. -Randomized, double-blind, placebo-controlled parallel group study-

Acronym

A study to confirm the reduction effect of the test food on abdominal visceral fat.

Scientific Title

A study to confirm the reduction effect of the test food on abdominal visceral fat. -Randomized, double-blind, placebo-controlled parallel group study-

Scientific Title:Acronym

A study to confirm the reduction effect of the test food on abdominal visceral fat.

Region

Japan


Condition

Condition

Healthy volunteer

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate for reduction of abdominal visceral fat when the test food for 12 weeks for healthy adult males and females with BMI of 23.0 or more and less than 30.0 kg/m2

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Abdominal visceral fat area

Key secondary outcomes

abdominal subcutaneous fat area, abdominal total fat area, body weight, BMI, body fat percentage, waist circumference, hip circumference, W/H ratio, triceps skinfold thickness, subscapular skinfold thickness, LDL- cholesterol, HDL- cholesterol, L/H ratio, triglyceride, glucose, HbA1c. resting energy expenditure, survey


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake of test food for 12 weeks

Interventions/Control_2

Intake of placebo food for 12 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1) Healthy Japanese males and females aged of 20-64 years
2) Subjects with BMI >=23.0 kg/m2 and <30.0 kg/m2 in screening test 1
3) Subjects with LDL-cholesterol <=159 mg/dL in screening test 1
4) Subjects who can visit on schedule days
5) Subjects who recognize the object and contents of the study and submit the written informed consent

Key exclusion criteria

1) Subjects who are under treatment or have a history of severe illness in the heart, liver, kidney, digestive organs or other organs
2) Subjects who are under treatment of dyslipidemia, high blood pressure, or diabetes
3) Subjects who received medication treatment or surgery due to serious illness or injury within 1 month from the start of this study
4) Subjects who regularly use health foods and supplements affecting the study
5) Possible pregnancy, pregnancy, and lactation
6) Heavy drinkers
7) Subjects who have experienced feel bad mood by blood collection
8) Subjects who donated 200 mL or more of blood within 1 month from the start of the study or subjects who plan to do so during the study period
9) Subjects who defecate less than once a week
10) Night Rotation worker
11) Subjects who plan business trip or trip for 10 days or more a month
12) Subjects who have allergy related to the test foods
13) Subjects with claustrophobia that interferes with CT scans, subjects with metal in the CT scan measurement site due to surgery, subjects with implanted medical devices such as cardiac pacemakers, implantable cardioverter defibrillators
14) Subjects already participating in other clinical trials
15) Subjects who are ineligible due to physician's judgment

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Ikuo
Middle name
Last name Fukuhara

Organization

Fukuhara Clinic

Division name

Hospital director

Zip code

061-1351

Address

3-1-15 Shimamatsuhigashi-machi, Eniwa, Hokkaido, Japan

TEL

0123-36-8029

Email

i-feniwa@gray.plala.or.jp


Public contact

Name of contact person

1st name Toyotada
Middle name
Last name Ashino

Organization

New drug research center, Inc.

Division name

Clinical Research Dept.

Zip code

061-1405

Address

452-1 Toiso, Eniwa, Hokkaido, Japan

TEL

0123-34-0412

Homepage URL


Email

t-ashino@ndrcenter.co.jp


Sponsor or person

Institute

New drug research center, Inc.

Institute

Department

Personal name



Funding Source

Organization

TOKIWA PHYTOCHEMICAL Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Corporation Jikokai Fukuzumi Internal Medicine Clinic Clinical Trial Review Committee

Address

1-2-5 Itoyokado Fukuzumiten-5F Fukuzumi-2jo, Toyohira-ku, Sapporo, Hokkaido, Japan

Tel

011-836-3531

Email

shibata@jkkai.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 06 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

44

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2023 Year 04 Month 18 Day

Date of IRB

2023 Year 04 Month 24 Day

Anticipated trial start date

2023 Year 08 Month 24 Day

Last follow-up date

2023 Year 11 Month 25 Day

Date of closure to data entry

2024 Year 01 Month 16 Day

Date trial data considered complete

2024 Year 01 Month 30 Day

Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 06 Month 05 Day

Last modified on

2023 Year 12 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000058455


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name